Phase 1 Trial

Vivani expects to initiate a Phase 1, randomized, first‑in‑human study evaluating NPM‑139 in mid‑2026, with Wegovy injections as an active comparator. The study's objectives are to characterize the safety, pharmacokinetics, and tolerability of NPM‑139 to support the initiation of a Phase 2 dose‑ranging study pending successful results.